B03 Nano immunotherapeutics crossing BBB for delivery of checkpoint inhibitors and activation of local brain tumor immune systems for glioma treatment. Julia Ljubimova, Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA.

B04 Glioblastoma elicits a greater degree of T-cell exhaustion than other intracranial tumors. Kristen Rhodin, Duke University School of Medicine, Durham, NC.

B05 Responsiveness to anti-PD1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Vassilis Genoud, University of Geneva, Geneva, Switzerland.

B06 p53 regulates immunogenicity of medulloblastoma. Alexandra Garancher, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

B07 Immunologic activation in recurrent high-grade glioma patients with durable complete response following treatment with Toca 511 and Toca FC. Clark Chen, University of Minnesota, Minneapolis, MN.

B08 Toca 511 and Toca FC: Durable complete responses observed in patients with IDH1 wild-type and mutant recurrent high-grade glioma (rHGG). Bob Carter, Massachusetts General Hospital, Boston, MA.

B09 Immunovirotherapy for gliomas: Clinical experience with DNX-2401 in combination with temozolomide for recurrent gliomas. Marc Garcia-Moure, University Hospital of Navarra, Pamplona, Navarra, Spain.


B12 Estradiol modulates early immune-surveillance in the brain metastatic niche to promote brain metastasis. Diana Cittelly, University of Colorado AMC, Aurora, CO.

B13 Contraction of T-cell richness in brain metastases of non-small cell lung cancers. Aaron Mansfield, Mayo Clinic, Rochester, MN.

B14 Integrated omics analysis of temporal changes of neoantigen and tumor microenvironment in primary and recurrent gliomas. Takahide Nejo, Department of Neurosurgery, The University of Tokyo, Tokyo, Japan.
B15  Mass cytometry identification of myeloid-derived suppressor cells as a biomarker and therapeutic target in glioblastoma. Tyler Alban, Cleveland Clinic Lerner Research Institute, Cleveland, OH.

B16  A 3D hydrogel culture system facilitates study of primary pediatric low-grade glioma cells in vitro. Christopher Rota, Dana-Farber Cancer Institute, Boston, MA.

B17  Roles of neutrophils in c-Met mediated breast cancer brain metastasis. Fei Xing, Wake Forest School of Medicine, Winston-Salem, NC.

B18  Landscape of immune response components heterogeneity in Finnish diffuse glioma patients. Ismail Hermelo, University of Tampere, Tampere, Pirkanmaa, Finland.


B20  Computational characterization of suppressive immune microenvironments in glioblastoma. Suvi Luoto, University of Tampere, Tampere, Pirkanmaa, Finland.

B21  Podoplanin-positive cells of the glioma microenvironment promote tumor progression. Tanja Eisemann, German Cancer Research Center (DKFZ), Heidelberg, Baden-Wuerttemberg, Germany.

B22  NEO214-induced ER stress results in glioblastoma DR5 neoantigen expression, resulting in suicide killing via astrocyte-secreted TRAIL ligands within the glioma microenvironment. Thomas Chen, University of Southern California, Los Angeles, CA.

B23  Vascular niche regulates alternative macrophage activation in glioblastoma immunity. Yi Fan, University of Pennsylvania, Philadelphia, PA.

B24  TGFβ inhibition improves response to radiotherapy in brain tumors and promotes the generation of myeloid-derived suppressive cells. Alba Gonzalez Junca, University of California San Francisco, San Francisco, CA.

B25  Meditone-enabled chimeric antigen receptor confers new functionality to the T cells. Cheng-Fu Kuo, City of Hope, Duarte, CA.

B26  IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Derek Wainwright, Northwestern University Feinberg School of Medicine, Chicago, IL.

B27  Antitumor efficacy of anti-PDL-1 in ACTH-secreting pituitary adenomas: An immunotherapeutic approach for Cushing’s disease. Hanna Kemeny, Duke University, Durham, NC.


B29  SYMPHONY: A novel synergistic nanotechnology-based platform for the improvement of laser interstitial thermal therapy. Hanna Kemeny, Duke University, Durham, NC.
B30  Noninvasive monitoring of in situ immunotherapeutic responses in glioblastoma using novel PET and MRI techniques. Joseph Antonios, University of California Los Angeles, Los Angeles, CA.

B31  Improved survival and immunostimulatory reprogramming in a preclinical glioblastoma model by combining antiangiogenic with immune checkpoint therapy. Karl H. Plate, Goethe University Medical Center, Frankfurt, Hessen, Germany.

B33  Triple combination immunotherapy with vaccination, PD-1 blockade, and OX40 ligation is highly effective against murine intracranial glioma. William Curry, Massachusetts General Hospital, Boston, MA.

B34  Early results of a phase I and open-label, randomized phase II study testing the toxicities and efficacy of pembrolizumab in combination with MRI-guided laser interstitial thermal therapy (LITT) in recurrent malignant gliomas. Jian Campian, Washington University School of Medicine, St. Louis, MO.